"Sanofi-Aventis (SNY), a pharmaceutical products company, is a buy based on our 'Benjamin Graham value' model," says John Reese who assesses stocks based on the investment criteria of numerous "legendary" investors.

The editor of Validea, explains, "Indeed, the stock earns a 100% score, meeting all of the investment criteria we review in for this value-oriented screen.

Continue reading Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model

Sanofi-Aventis (SNY): 100% Score on a Ben Graham Value Model originally appeared on BloggingStocks on Fri, 01 Apr 2011 12:00:00 EST. Please see our terms for use of feeds.

"We follow an approach to investng that focuses on broadly diversified investments in undervalued stocks for their long-term appreciation potential," says value investor John Buckingham.

The money manager and editor of The Prudent Speculator explains, " Two recently featured ideas -- Abbott Laboratories (ABT) and Baxter International (BAX) -- are among those we feel could serve as a portfolio foundation or as a new ideas for well- diversified holdings.

Continue reading Abbott (ABT) and Baxter (BAX): Healthy Gains

Abbott (ABT) and Baxter (BAX): Healthy Gains originally appeared on BloggingStocks on Tue, 01 Mar 2011 10:00:00 EST. Please see our terms for use of feeds.

"Novo Nordisk A/S (NVO) is a Danish pharmaceutical company that focuses on diabetes care and biopharmaceuticals," notes Nicholas Vardy.

The editor of the Global Bull Market Alert explains, "Novo Nordisk is a quiet giant, employing 30,000 people in 76 countries; we think investors could double their money with this profit machine.

"More than 200 million people worldwide suffer from some form of diabetes. Patients with type 1 (juvenile) diabetes can't make insulin at all and need to inject it their whole lives.

Continue reading Novo Nordisk A/S (NVO): Health Care 'Profit Machine'

Novo Nordisk A/S (NVO): Health Care 'Profit Machine' originally appeared on BloggingStocks on Wed, 23 Feb 2011 13:00:00 EST. Please see our terms for use of feeds.

"The visible growth story at Jazz Pharmaceuticals (JAZZ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues," says growth stock specialist Mike Cintolo.

The editor of Cabot Top Ten Weekly Report explains, "But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain.

"Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome.

Continue reading All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety

All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety originally appeared on BloggingStocks on Tue, 08 Feb 2011 11:00:00 EST. Please see our terms for use of feeds.

The editor of Dow Theory Forecasts explains, "One exception is Abbott Laboratories (ABT); Wall Street expects to increase earnings at a 10% annual rate over the next five years.

"Yet the market appears to discount that outlook, and the stock's price/earnings-to-growth ratio (PEG) of 1.2 is well below its peers.

Continue reading Abbott Labs (ABT): A Rich Pipeline in Pharma

Abbott Labs (ABT): A Rich Pipeline in Pharma originally appeared on BloggingStocks on Wed, 01 Dec 2010 10:20:00 EST. Please see our terms for use of feeds.

"Johnson & Johnson (JNJ) is an international giant, employing more than 115,000 people and operating in 60 countries," notes Gavin Graham.

The contributing analyst to Internet Wealth Builder explains, "The conservative stock is in a great business in an almost recession-proof field. Indeed, we see this an opportunity to buy a world-class stock at a reasonable price.

"It is a major provider of prescription drugs, including Remicade for arthritis and Procrit for red blood cell production.

Continue reading Johnson & Johnson (JNJ): World Class Buy

Johnson & Johnson (JNJ): World Class Buy originally appeared on BloggingStocks on Tue, 09 Nov 2010 10:30:00 EST. Please see our terms for use of feeds.

The editor of Validea continues, "Sanofi-Aventis (SNY), which is involved in pharmaceuticals and human vaccines, earns a Guru Score of 100% based on the value investing strategy of Benjamin Graham.

"In its pharmaceutical activity, the company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system (CNS), and internal medicine.

Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy

Sanofi-Aventis (SNY): A Ben Graham Value Buy originally appeared on BloggingStocks on Mon, 25 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

The editor of Cabot Benjamin Graham Value Letter explains, "Gilead is a biopharmaceutical company that discovers, develops and markets therapeutic treatments to combat viral, bacterial and fungal infections. Its shares undervalued at 9.7 times forward 12-month EPS.

"Teva, based in Israel, develops, makes and sells generic and proprietary-branded (store brand) drugs. Its shares are clearly undervalued at 10.6 times forward EPS. We consider both stocks to be very low risk.

Continue reading Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA)

Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA) originally appeared on BloggingStocks on Thu, 14 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

"Foreign corporations have been on a mini buying spree in 2010. Not surprising, merger and acquisition activity has heated up a bit in the drug sector," says Chuck Carlson, editor of The DRIP Investor.

The dividend expert explains, " Global merger and acquisition activity topped $1 trillion in the first half of 2010, a 9.4% increase over the previous year. And Bristol-Myers Squibb (BMY), recommend stock in our Editor's Portfolio, has been one of the more active participants.

Continue reading Bristol-Myers Squibb (BMY): Buying Growth?

Bristol-Myers Squibb (BMY): Buying Growth? originally appeared on BloggingStocks on Wed, 29 Sep 2010 13:00:00 EST. Please see our terms for use of feeds.

"For years the health care sector had a well-deserved reputation for consistent returns and profitability regardless of broader economic conditions," observes Elliott Gue.

The contributing editor to Personal Finance explains, "But the past two years have challenged this reputation, and these stocks are out of favor. Some favorites, such as Novartis (NVS) are trading at their most attractive valuation in years.

"Although the sector faces undeniable challenges, markets often overreact to new regulation, providing attractive entry points for savvy investors and a low bar of expectations.

Continue reading Novartis (NVS): Pharma Favorite with Solid Pipeline

Novartis (NVS): Pharma Favorite with Solid Pipeline originally appeared on BloggingStocks on Thu, 26 Aug 2010 13:00:00 EST. Please see our terms for use of feeds.

"New products are the life-blood of any pharmaceutical company. Unfortunately, blockbuster drug breakthroughs have been fairly rare in recent years, lowering valuations for pharmaceutical stocks," says Chuck Carlson.

The editor of The DRIP Investor, which focuses on dividend reinvestment strategies, explains, "The good news is that the lone drug stock in the Editor's Portfolio, Bristol-Myers Squibb (BMY), has had a spate of good news recently on the drug-development front.

"The company recently announced that a mid-stage trial of an experimental arthritis drug had met its goal, supporting further development of the drug.

Continue reading Bristol-Myers Squibb (BMY): 'Solid, Quality Play'

Bristol-Myers Squibb (BMY): 'Solid, Quality Play' originally appeared on BloggingStocks on Mon, 26 Jul 2010 10:00:00 EST. Please see our terms for use of feeds.

Continue reading Teva (TEVA): A 'Sure Pick' for the Long-Term

Teva (TEVA): A 'Sure Pick' for the Long-Term originally appeared on BloggingStocks on Tue, 20 Jul 2010 12:30:00 EST. Please see our terms for use of feeds.

"Sanofi-Aventis (SNY) is a pharmaceutical group engaged in the research, development, manufacture and marketing of health care products; the stock gets a 100% score in meeting the criteria for our investment screen based on d value investing criteria used by the legendary Benjamin Graham," says John Reese.

The editor of Validea newsletter explains, "The company's business includes two main activities: pharmaceuticals and human vaccines. The company is also present in animal health products.

"In its pharmaceutical activity, the Company specializes in six therapeutic areas: diabetes, oncology, thrombosis and cardiovascular, central nervous system), and internal medicine.

Continue reading Sanofi-Aventis (SNY): A Ben Graham Value Buy

Sanofi-Aventis (SNY): A Ben Graham Value Buy originally appeared on BloggingStocks on Wed, 30 Jun 2010 10:15:00 EST. Please see our terms for use of feeds.

Continue reading Johnson & Johnson (JNJ) : 'Dirt Cheap Valuation'

Johnson & Johnson (JNJ) : 'Dirt Cheap Valuation' originally appeared on BloggingStocks on Tue, 29 Jun 2010 10:00:00 EST. Please see our terms for use of feeds.

"Modern drugs are expensive to develop; but after just 20 years, a drug can be duplicated by generic drug manufacturers and sold to those who need it for far less money," says Paul Goodwin.

The editor of Cabot China & Emerging Markets Report explains, "That's where Dr. Reddy's Laboratories (RDY) comes in. Founded in 1984 by Dr. Anji Reddy, Dr. Reddy's Labs is the main reason India has gone from a net drug importer to a net drug exporter.

"Dr. Reddy's is a growing global power in the pharmaceutical business, with a lineup of more than 50 products offered in the U.S., more than 160 products marketed in Europe, and more than 200 branded formulations available in India, Russia and other emerging markets.

Continue reading Dr. Reddy's (RDY): A 'Generic Revolution'

Dr. Reddy's (RDY): A 'Generic Revolution' originally appeared on BloggingStocks on Mon, 21 Jun 2010 11:10:00 EST. Please see our terms for use of feeds.

Continue reading Teva (TEVA): Generic Gains from Health Care Reform

Teva (TEVA): Generic Gains from Health Care Reform originally appeared on BloggingStocks on Thu, 13 May 2010 14:00:00 EST. Please see our terms for use of feeds.

"It's time for income investors to come back to what's historically been a mainstay of diversified portfolios: big pharmaceutical companies. We're adding one of the sector's most durable members to the Income Portfolio, Bristol-Myers Squibb (BMY)," says Roger Conrad.

In Personal Finance newsletter, he explains, "The stock has been a lackluster performer since the 1990s, when it was last a Portfolio recommendation. The company's underlying business, however, has become ever-more valuable.

Continue reading Bristol-Myers Squibb (BMY): Time to Buy Pharma

Bristol-Myers Squibb (BMY): Time to Buy Pharma originally appeared on BloggingStocks on Thu, 25 Feb 2010 11:00:00 EST. Please see our terms for use of feeds.

"The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.

In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA).

Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic drugs. Capitalized at $49 billion, Teva pulled in some $11 billion in revenues in 2008, with generic drugs contributing more than two-thirds of those sales.

Continue reading Teva (TEVA): Baby-boomers give boost to generics

Teva (TEVA): Baby-boomers give boost to generics originally appeared on BloggingStocks on Wed, 14 Oct 2009 11:00:00 EST. Please see our terms for use of feeds.

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Turnaround expert targets laggard pharmaceuticals originally appeared on BloggingStocks on Mon, 12 Oct 2009 12:10:00 EST. Please see our terms for use of feeds.

The Cabot Benjamin Graham Value Letter focuses on stocks that meet the strict value criteria of the legendary investor. Here, J. Royden Ward looks to Teva Pharmaceutical (NASDAQ: TEVA), noting, "Teva is based in Israel and develops, makes and sells generic and proprietary-branded (store brand) drugs."

The advisor explains, "The company is one of the largest generic drug-producing companies in the world and, in addition, sells active ingredients to other pharmaceutical companies.

"Teva's aggressive acquisition and product development programs are driving strong sales growth. The company recently purchased U.S.-based Barr Pharmaceuticals for $7.5 billion. Barr will increase Teva's generic drug sales significantly in the U.S. and parts of Europe.

Continue reading Teva: A 'Ben Graham' selection

Teva: A 'Ben Graham' selection originally appeared on BloggingStocks on Fri, 18 Sep 2009 13:30:00 EST. Please see our terms for use of feeds.